Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with immune-mediated myositis and necrotizing myopathy|
|Citation:||Muscle and Nerve, 2015; 52(2):196-203|
|Vidya Limaye, Chris Bundell, Peter Hollingsworth, Arada Rojana-Udomsart, Frank Mastaglia, Peter Blumbergs and Sue Lester|
|Abstract:||Introduction: Inhibition of 3-hydroxy-3-methylglutaryl- coenzyme A reductase (HMGCR) with statins may trigger idiopathic inflammatory myositis (IIM) or immune-mediated necrotizing myopathy (IMNM). Anti-HMGCR antibodies have been detected in patients with IIM/IMNM. We aimed to determine the associations of anti-HMGCR in IIM/IMNM. Methods: Anti-HMGCR antibodies were detected by ELISA in sera from patients with IIM/IMNM. Results: Anti-HMGCR antibodies were detected in 19 of 207 patients with IIM/IMNM, and there was a trend toward an association with male gender (P50.079). Anti- HMGCR antibodies were associated strongly with statin exposure (OR539, P50.0001) and HLA-DRB1*11 (OR550, P<0.0001). The highest risk for development of anti-HMGCR antibodies was among HLA-DR11 carriers exposed to statins. Univariate analysis showed a strong association of anti- HMGCR antibodies with diabetes mellitus (P50.008), which was not confirmed by multiple regression. Among anti- HMGCR⁺ patients there was a trend toward increased malignancy (P50.15). Conclusions: Anti-HMGCR antibodies are seen in all subtypes of IIM and IMNM and are associated strongly with statin use and HLA-DR11.|
|Keywords:||Antibodies; HMG-CoA reductase; immune-mediated necrotizing myopathy; muscle biopsy; myositis; statins|
|Rights:||© 2014 Wiley Periodicals, Inc.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.